MRSN — Mersana Therapeutics Share News
0.000.00%
Last trade - 00:00- $145.16m
- $88.77m
- $40.50m
Mersana Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Mersana Therapeutics Inc - Expect Capital Resources Will Support Current Operating Plan Commitments Into 2026
Brief: Mersana Therapeutics Says Co And Merck KGaA Mutually Agreed To Terminate Collaboration And Commercial License Agreement Dated June 23, 2014
Brief: Mersana Therapeutics Capital Resources Expected To Support Current Operating Plan Commitments Into 2026
Brief: Mersana Therapeutics Q3 EPS USD -0.35
Mersana Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Mersana Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Mersana Therapeutics Announces Second Quarter 2023 Financial Results
Mersana Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Ecor1 Capital Reports 16.9% Passive Stake In Mersana Therapeutics Inc As Of July 27
U.S. STOCKS ON THE MOVE-Tupperware, Equitrans Midstream, Cutera
U.S. STOCKS ON THE MOVE-Hershey, Microsoft, Mastercard
Mersana Therapeutics plummets after cancer drug fails study
Brief: Mersana Therapeutics Announces Topline Data From Uplift Clinical Trial In Patients With Platinum-Resistant Ovarian Cancer And Strategic Reprioritization
U.S. RESEARCH ROUNDUP-Adobe, Par Technology, Toast
U.S. STOCKS ON THE MOVE-Adobe, Nikola, copper miners
U.S. STOCKS ON THE MOVE-Premier, Canadian Solar, Jabil
U.S. STOCKS ON THE MOVE-Premier, Canadian Solar, Jabil
Mersana falls as FDA halts enrollment in cancer drug studies